The company will report its earnings for FY 2018 on 03/28/2019. Generally, the company reports earnings better than estimates. In recent months, the analysts from Thomson Reuters consensus have revised their EPS estimates downward.
Annual earnings per share is expected at 0.12 PLN for 2018 (- 75% from 2017). A summary of annual publications and estimates is available below.
Ryvu Therapeutics SA, formerly known as Selvita SA, is a Poland-based company engaged in the healthcare industry. The Company is active in the pharmaceutical and biotechnology fields. It operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Companyâs portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. It operates through unit Ardigen SA and SORS Holdings Ltd.
RYVU THERAPEUTICS S.A. 
